WO2012103071A3 - Compounds and compositions - Google Patents

Compounds and compositions Download PDF

Info

Publication number
WO2012103071A3
WO2012103071A3 PCT/US2012/022333 US2012022333W WO2012103071A3 WO 2012103071 A3 WO2012103071 A3 WO 2012103071A3 US 2012022333 W US2012022333 W US 2012022333W WO 2012103071 A3 WO2012103071 A3 WO 2012103071A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
methyl
halo
methoxy
fluoromethyl
Prior art date
Application number
PCT/US2012/022333
Other languages
French (fr)
Other versions
WO2012103071A2 (en
Inventor
Peter Bertinato
Takashi Satoh
Mark Spyvee
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of WO2012103071A2 publication Critical patent/WO2012103071A2/en
Publication of WO2012103071A3 publication Critical patent/WO2012103071A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

The present invention provides compounds of Formula (I), wherein: R1a and R1b are independently hydrogen or methyl; or R1a and R1b are taken together to form a cyclopropyl ring; R2 is methyl or fluoromethyl; R3 is methyl; R4 is hydrogen, halo, fluoromethyl, methoxy, or fluoromethoxy; R5 is hydrogen, halo, fluoromethyl, methoxy, or fluoromethoxy; R6 is hydrogen, halo, methyl, or methoxy; R7 is hydrogen, halo, methyl, or methoxy; X is CH(R8); and R8 is hydrogen or C1-C6 alkyl or cycloalkyl; or pharmaceutically acceptable salts thereof. Compositions and methods of use thereof are also described.
PCT/US2012/022333 2011-01-25 2012-01-24 Compounds and compositions WO2012103071A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161435924P 2011-01-25 2011-01-25
US61/435,924 2011-01-25

Publications (2)

Publication Number Publication Date
WO2012103071A2 WO2012103071A2 (en) 2012-08-02
WO2012103071A3 true WO2012103071A3 (en) 2014-04-17

Family

ID=46581354

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/022333 WO2012103071A2 (en) 2011-01-25 2012-01-24 Compounds and compositions

Country Status (1)

Country Link
WO (1) WO2012103071A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510121RA (en) 2013-06-12 2016-01-28 Kaken Pharma Co Ltd 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
TW201623277A (en) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 Amide compound
KR20180083863A (en) 2015-10-16 2018-07-23 에자이 알앤드디 매니지먼트 가부시키가이샤 EP4 antagonist
CR20180323A (en) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd DERIVATIVES OF INDOL N-SUBSTITUTES AS MODULATORS OF PGE2 RECEIVERS
MX2019013639A (en) 2017-05-18 2020-01-21 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives.
ES2896476T3 (en) 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
EA201992677A1 (en) 2017-05-18 2020-04-23 Идорсия Фармасьютиклз Лтд PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
MX2019013718A (en) 2017-05-18 2020-01-30 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators.
AR111807A1 (en) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd BENZOFURAN AND BENZOTIOPHENE DERIVATIVES AS MODULATORS OF THE PGE2 RECEIVER
KR20210040064A (en) 2018-07-12 2021-04-12 로타팜 바이오테크 에스.알.엘 (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl benzoic acid as EP4 receptor antagonist
WO2022102731A1 (en) 2020-11-13 2022-05-19 小野薬品工業株式会社 Cancer treatment by combined use of ep4 antagonist and immune checkpoint inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070112192A1 (en) * 2002-12-05 2007-05-17 Vernalis (Cambridge) Limited 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer
WO2009137338A1 (en) * 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
WO2010014453A1 (en) * 2008-07-31 2010-02-04 Merck & Co., Inc. Inhibitors of janus kinases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070112192A1 (en) * 2002-12-05 2007-05-17 Vernalis (Cambridge) Limited 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer
WO2009137338A1 (en) * 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
WO2010014453A1 (en) * 2008-07-31 2010-02-04 Merck & Co., Inc. Inhibitors of janus kinases

Also Published As

Publication number Publication date
WO2012103071A2 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
WO2012103071A3 (en) Compounds and compositions
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
UA109883C2 (en) A METHOD OF OBTAINING COMPOUNDS FOR APPLICATION AS SGLT2 INHIBITORS
MD20180040A2 (en) Inhibitors of hepatitis C virus
EA201201377A1 (en) DEFINED AMINOPIRIDAZINES, COMPOSITIONS ON THEIR BASIS AND METHODS OF THEIR USE
MX2016006336A (en) Pyrazolopyrimidine compounds.
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
IN2014MN01521A (en)
MY172860A (en) Dimethyl-benzoic acid compounds
MX2013013041A (en) Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt).
WO2010091892A3 (en) Alkylamido compounds and uses thereof
WO2012117357A3 (en) Process for preparation of ketolide intermediates
WO2012042534A3 (en) Preparation of r-sitagliptin and intermediates thereof
MX2013000295A (en) Process of preparing a thrombin specific inhibitor.
PH12015500009A1 (en) Phenoxyethyl piperidine compounds
IN2014CN04449A (en)
MY160321A (en) Pesticidal composition and its use
IN2014CN00302A (en)
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
IN2014MN00850A (en)
MX2013000294A (en) Intermediates and process for preparing a thrombin specific inhibitor.
MX2010009926A (en) New process for the preparatiion of cyclohexanecarboxylic acid dericatives.
MX346980B (en) New hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds.
MX2013002656A (en) New process.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12739798

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12739798

Country of ref document: EP

Kind code of ref document: A2